Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totaling 15,000 shares, an increase of 57.9% from the September 30th total of 9,500 shares. Based on an average daily volume of 31,500 shares, the short-interest ratio is presently 0.5 days. Approximately 1.8% of the company’s stock are sold short. Approximately 1.8% of the company’s stock are sold short. Based on an average daily volume of 31,500 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. HC Wainwright downgraded shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Price Performance

NASDAQ:SNSE opened at $9.17 on Friday. The firm has a 50-day moving average of $9.74 and a 200-day moving average of $8.34. The company has a market cap of $11.55 million, a PE ratio of -0.43 and a beta of 0.31. Sensei Biotherapeutics has a one year low of $5.00 and a one year high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($3.91) earnings per share for the quarter, topping the consensus estimate of ($6.20) by $2.29. On average, equities research analysts expect that Sensei Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.